Metopocor

Metoprolol Tartrate, the active ingredient in Metopocor, is a beta blocker presented as an injectable solution for intravenous use. It treats hypertension, angina pectoris, acute myocardial infarction, heart failure, and cardiac arrhythmias in adult patients.

GNH USA supplies Metopocor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopocor (metoprolol tartrate) is used in cardiovascular conditions where β1‑adrenergic blockade reduces cardiac workload.

Hypertension: lowers blood pressure by decreasing heart rate and contractility. Angina pectoris: reduces myocardial oxygen demand, relieving chest pain. Acute myocardial infarction: improves survival by limiting cardiac stress. Heart failure: enhances ventricular function and reduces symptoms. Cardiac arrhythmias: stabilizes heart rhythm by controlling rate.

Metopocor may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness. - Dizziness: light‑headedness on standing. - Bradycardia: slower heart rate. - Gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure drop. - Heart block: impaired cardiac conduction. - Bronchospasm: airway narrowing, especially in asthmatics. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Metopocor, clinicians should consider several safety measures to minimize risks. - Assess cardiovascular status: evaluate heart rate, blood pressure, and conduction before initiation. - Review concomitant β‑blockers: avoid additive effects that may cause excessive bradycardia. - Monitor renal and hepatic function: dose adjustments may be needed in impairment. - Caution in asthma or COPD: selective β1 blockade can still provoke bronchospasm. - Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metopocor can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Calcium channel blockers (e.g., verapamil, diltiazem): can cause profound bradycardia or AV block. - Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of conduction disturbances. - Clonidine abrupt withdrawal: may precipitate severe hypertension when combined. - Non‑selective β‑blockers: additive β‑blocking effects leading to hypotension.

Moderate Interactions (Monitor Closely): - Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycemia symptoms. - NSAIDs: can reduce antihypertensive effect. - ACE inhibitors or ARBs: may enhance hypotensive response. - Lipid‑lowering agents (statins): increased risk of myopathy.